Randomized controlled trial2022

Intermittent Fasting in Weight Loss and Cardiometabolic Risk Reduction: A Randomized Controlled Trial

Chair SY, Cai H, Cao X, Qin Y, Cheng HY, Ng MT

The journal of nursing research : JNR · 41 citations

Review labels

Funding not disclosed

Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.

How it was studied

Design
Randomized controlled trial (indexed by PubMed)
Studied in
People
Main outcome
Health markers and function

Who paid for it

Funding
Funding not disclosed

Publication

Published
2022-01-20 · J Nurs Res · vol. 30 · issue 1 · p. e185
Publisher
Wolters Kluwer
Cited
76 citations · more than 98% of similar papers · 7.5× the field average
Impact
Top 10% most cited in its field
References
28 works
Access
Open access (free to publish) · CC-BY
Research areas
Dietary Effects on Health · Diet and metabolism studies · Genetics, Aging, and Longevity in Model Organisms
Keywords
Prediabetes, Overweight, Body mass index, Medicine, Waist, Weight loss, Randomized controlled trial, Internal medicine, Obesity, Intermittent fasting, Endocrinology, Diabetes mellitus, Type 2 diabetes
MeSH
humans, cardiovascular diseases, weight loss, fasting, risk reduction behavior, adult, overweight

6 authors

From HK, CN

  • Sek Ying ChairChinese University of Hong Kong
  • Hua “Linda” CaiHunan Provincial People's Hospital
  • Xi Cao · correspondingChinese University of Hong Kong
  • Yuelan QinHunan Provincial People's Hospital
  • Ho Yu ChengChinese University of Hong Kong
  • Michael Timothy Ng

Abstract

Background

Intermittent fasting is an effective approach to promote weight loss. The optimal model of intermittent fasting in achieving weight management and cardiometabolic risk reduction is an underexplored but important issue.

Purpose

This study was designed to examine the effects of alternate-day fasting (ADF) and 16/8 time-restricted fasting (16/8 TRF) on weight loss, blood glucose, and lipid profile in overweight and obese adults with prediabetes.

Methods

A randomized controlled trial was conducted on a sample of 101 overweight and obese adults with prediabetes. The participants were randomized into the ADF group (n = 34), 16/8 TRF group (n = 33), and control group (n = 34). The intervention lasted for 3 weeks. Data on body weight, body mass index, waist circumference, blood glucose, and lipid profile were collected at baseline, at the end of the intervention, and at the 3-month follow-up.

Results

The reductions in body weight, body mass index, and waist circumference in the ADF and 16/8 TRF groups were more significant than those in the control group across the study period (all ps < .05). Moreover, significant reductions on blood glucose and triglycerides were observed in the two intervention groups as well. Furthermore, the reductions in body weight and body mass index in the ADF group were more significant than those in the 16/8 TRF group (all ps < .001). However, differences on the changes in blood glucose, waist circumference, and low-density lipoprotein cholesterol between the two intervention groups were not significant.

Conclusions/implications for practice

The benefits of ADF and 16/8 TRF in promoting weight loss in overweight/obese adults with prediabetes were shown in this study. ADF was shown to have more-significant reduction effects on body weight and body mass index than 16/8 TRF. These findings indicate the potential benefit of integrating intermittent fasting regimens into normal dietary patterns to reduce the risk of diabetes and cardiovascular disease in this population.

Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).

Community trust

Loading…

How much do you trust this study's findings?

0 · not at all10 · completely

Comments

Sign in to rate, comment on or flag this study.Sign in

Something wrong here?

Flag this study if its information, labels or funding look wrong. An editor reviews every flag.

Sign in to rate, comment on or flag this study.Sign in

Educational information about published research. Not medical advice, and not a recommendation to start or stop anything.